Study identification

EU PAS number

EUPAS10688

Study ID

27984

Official title and acronym

Comparing Common Safety Outcomes in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Various First-line Platinum-containing Chemotherapy Combination Regimens (H3E-MC-B026)

DARWIN EU® study

No

Study countries

United States

Study status

Finalised
Research institutions and networks

Institutions

Contact details

Sangmi Kim

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable